{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:15:26Z","timestamp":1761513326380,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.eplepsyres.2013.06.020","type":"journal-article","created":{"date-parts":[[2013,7,31]],"date-time":"2013-07-31T18:16:24Z","timestamp":1375294584000},"page":"417-422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Early detection of bone metabolism changes under different antiepileptic drugs (ED-BoM-AED) \u2013 A prospective multicenter study"],"prefix":"10.1016","volume":"106","author":[{"given":"Sebastian","family":"Bauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenz C.","family":"Hofbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Rauner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Strzelczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Kellinghaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Hallmeyer-Elgner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang H.","family":"Oertel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Rosenow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2013.06.020_bib0005","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1528-1167.2007.00924.x","article-title":"A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on cyp3a4","volume":"48","author":"Andreasen","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2013.06.020_bib0010","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3988\/jcn.2012.8.1.65","article-title":"May long term oxcarbazepine treatment be lead to secondary hyperparathyroidism?","volume":"8","author":"Babacan","year":"2012","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.eplepsyres.2013.06.020_bib0015","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.phrs.2003.11.011","article-title":"The effect of valproate on bone mineral density in adult epileptic patients","volume":"50","author":"Boluk","year":"2004","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.eplepsyres.2013.06.020_bib0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2013.05.026","article-title":"CYP2C9 genotype and association with bone mineral density: a pilot study","author":"Brunner-Ziegler","year":"2013","journal-title":"Gene"},{"key":"10.1016\/j.eplepsyres.2013.06.020_bib0020","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.pediatrneurol.2008.07.001","article-title":"Evaluation of bone turnover in epileptic children using oxcarbazepine","volume":"39","author":"Cansu","year":"2008","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.eplepsyres.2013.06.020_bib0025","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00198-009-0838-9","article-title":"Bone turnover markers: understanding their value in clinical trials and clinical practice","volume":"20","author":"Civitelli","year":"2009","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.eplepsyres.2013.06.020_bib0030","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/382448a0","article-title":"Increased bone formation in osteocalcin-deficient mice","volume":"382","author":"Ducy","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.eplepsyres.2013.06.020_bib0035","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.pediatrneurol.2004.03.021","article-title":"Effect of carbamazepine and valproate on bone mineral density","volume":"31","author":"Ecevit","year":"2004","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.eplepsyres.2013.06.020_bib0040","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.eplepsyres.2008.03.008","article-title":"Fish liver oil and propolis as protective natural products against the effect of the anti-epileptic drug valproate on immunological markers of bone formation in rats","volume":"80","author":"Elwakkad","year":"2008","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2013.06.020_bib0045","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.0013-9580.2004.00104.x","article-title":"The activity of antiepileptic drugs as histone deacetylase inhibitors","volume":"45","author":"Eyal","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2013.06.020_bib0050","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/jcb.20217","article-title":"Regulation of RANKL promoter activity is associated with histone remodeling in murine bone stromal cells","volume":"93","author":"Fan","year":"2004","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.eplepsyres.2013.06.020_bib0055","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells","volume":"20","author":"G\u00f6ttlicher","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/j.eplepsyres.2013.06.020_bib0060","first-page":"569","article-title":"A comparative study of the relative influence of different anticonvulsant drugs. UV exposure and diet on vitamin D and calcium metabolism in out-patients with epilepsy","volume":"59","author":"Gough","year":"1986","journal-title":"Q. J. Med."},{"key":"10.1016\/j.eplepsyres.2013.06.020_bib0065","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2165\/00003495-197612030-00003","article-title":"Bone complications of anticonvulsants","volume":"12","author":"Hahn","year":"1976","journal-title":"Drugs"},{"key":"10.1016\/j.eplepsyres.2013.06.020_bib0070","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jama.292.4.490","article-title":"Clinical implications of the osteoprotegerin\/RANKL\/RANK system for bone and vascular diseases","volume":"292","author":"Hofbauer","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.eplepsyres.2013.06.020_bib0075","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/ije\/dys063","article-title":"Osteoprotegerin is associated with hip fracture incidence: the Tromso Study","volume":"41","author":"J\u00f8rgensen","year":"2012","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.eplepsyres.2013.06.020_bib0080","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1212\/01.wnl.0000247107.54562.0e","article-title":"Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone","volume":"67","author":"Mikati","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2013.06.020_bib0085","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/WCO.0b013e32833735e7","article-title":"Metabolic consequences of antiepileptic drugs","volume":"23","author":"Mintzer","year":"2010","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.eplepsyres.2013.06.020_bib0090","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1528-1167.2006.00460.x","article-title":"Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine","volume":"47","author":"Mintzer","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2013.06.020_bib0095","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1359\/jbmr.2000.15.5.863","article-title":"In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene","volume":"15","author":"Onyia","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.eplepsyres.2013.06.020_bib0100","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/ana.20378","article-title":"Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy","volume":"57","author":"Pack","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.eplepsyres.2013.06.020_bib0105","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen","volume":"276","author":"Phiel","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.eplepsyres.2013.06.020_bib0110","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1212\/WNL.57.3.445","article-title":"Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy","volume":"57","author":"Sato","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2013.06.020_bib0120","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S0022-3476(95)70304-7","article-title":"Effect of carbamazepine and valproate on bone mineral density","volume":"127","author":"Sheth","year":"1995","journal-title":"J. Pediatr."},{"key":"10.1016\/j.eplepsyres.2013.06.020_bib0125","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/j.0013-9580.2004.18804.x","article-title":"Fracture risk associated with use of antiepileptic drugs","volume":"45","author":"Vestergaard","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2013.06.020_bib0130","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1124\/mol.111.076356","article-title":"An inducible cytochrome P450 3A4-dependent vitamin D catabolic pathway","volume":"81","author":"Wang","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2013.06.020_bib0135","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.0306-5251.2001.01474.x","article-title":"In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9)","volume":"52","author":"Wen","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2013.06.020_bib0140","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1210\/jcem-58-6-1003","article-title":"Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment","volume":"58","author":"Weinstein","year":"1984","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.eplepsyres.2013.06.020_bib0145","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.addr.2004.12.013","article-title":"The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics","volume":"57","author":"Yasuda","year":"2005","journal-title":"Adv. Drug Deliv. Rev."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121113001848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121113001848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:29:52Z","timestamp":1760275792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121113001848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0920121113001848"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2013.06.020","relation":{},"ISSN":["0920-1211"],"issn-type":[{"type":"print","value":"0920-1211"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early detection of bone metabolism changes under different antiepileptic drugs (ED-BoM-AED) \u2013 A prospective multicenter study","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2013.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}